psma imaging pre- and post-177lu-psma-617 treatment in mcrpc
Published 3 months ago • 68 plays • Length 1:08Download video MP4
Download video MP3
Similar videos
-
5:30
fractionated dose 177lu-psma-617 in patients with mcrpc
-
5:27
177lu-psma-617 radionuclide therapy in mcrpc
-
3:03
vision: tolerability of 177lu-psma-617 by treatment exposure in patients with mcrpc
-
0:57
real-world outcomes of 177lu-psma-617 in mcrpc
-
1:00
is there are role for 177lu-psma-617 in earlier lines of treatment for mcrpc?
-
buletin utama, 8 ogos 2024
-
13:58
what is the best way to see if prostate cancer has spread?
-
6:43
does sugar feed prostate cancer? does fatty/adipose tissue attract cancer? | mark moyad, md, mph
-
1:28
vision: 177lu-psma-617 in psma-positive mcrpc
-
3:56
vision: 177lu-psma-617 in psma-positive mcrpc
-
1:38
dr. sartor on outcomes with 177lu-psma-617 after radium-223 in mcrpc
-
1:35
vision: safety analysis of 177lu-psma-617 in mcrpc
-
3:01
preliminary findings in mcrpc for fractionated dose 177lu-psma-617
-
4:48
vision: lu-177-psma-617 in mcrpc
-
6:45
177lu-psma-617 for prostate cancer: therap, vision, upfrontpsma and lutectomy
-
2:37
therap: cabazitaxel versus 177lu-psma-617 for mcrpc
-
1:02
dr. gafita on prognostic models for treatment with 177lu-psma-617 in mcrpc
-
![psmafore results: [177lu]lu-psma-617 in taxane-naive patients with mcrpc](https://i.ytimg.com/vi/upLVFTNeq9o/mqdefault.jpg)
10:20
psmafore results: [177lu]lu-psma-617 in taxane-naive patients with mcrpc
-
5:37
177lu-psma-617 for the early treatment of prostate cancer
-
1:50
dr. gafita on sequencing 177lu-psma-617 in mcrpc
-
5:45
efficacy and toxicity of 177lu-psma-617 for mcrpc in a real-world setting
-
3:17
safety and efficacy of 177lu-psma-617